Page 383 - Read Online

Page 18 of 19 Marasco et al. Hepatoma Res 2020;6:33 I http://dx.doi.org/10.20517/2394-5079.2020.01

drug-eluting beads chemoembolization for hepatocellular carcinoma. Dig Dis Sci 2019; Epub ahead of print. doi: 10.1007/s10620-019-
05951-6.
164. Kobayashi T, Kawai H, Nakano O, Abe S, Kamimura H, et al. Rapidly declining skeletal muscle mass predicts poor prognosis of
hepatocellular carcinoma treated with transcatheter intra-arterial therapies. BMC Cancer 2018;18:756.
165. Eggert T, Greten TF. Current standard and future perspectives in non-surgical therapy for hepatocellular carcinoma. Digestion
2017;96:1-4.
166. Minami Y. Radiofrequency ablation of hepatocellular carcinoma: current status. World J Radiol 2010;2:417.
167. Lau WY, Lai ECH. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann
Surg 2009;249:20-5.
168. Na BG, Kim JM, Oh DK, Lee KW, Kang TW, et al. Clinical outcomes of laparoscopic radiofrequency ablation of single primary or
recurrent hepatocellular carcinoma (≤ 3 cm). Ann Surg Treat Res 2017;92:355-60.
169. Lencioni R, Cioni D, Crocetti L, Franchini C, Della Pina C, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: Long-
term results of percutaneous image-guided radiofrequency ablation. Radiology 2005;234:961-7.
170. Nault JC, Sutter O, Nahon P, Ganne-Carrié N, Séror O. Percutaneous treatment of hepatocellular carcinoma: State of the art and
innovations. J Hepatol 2018;68:783-97.
171. Toshimori J, Nouso K, Nakamura S, Wada N, Morimoto Y, et al. Local recurrence and complications after percutaneous radiofrequency
ablation of hepatocellular carcinoma: a retrospective cohort study focused on tumor location. Acta Med Okayama 2015;69:205-12.
172. Tiong L, Maddern GJ. Systematic review and meta-analysis of survival and disease recurrence after radiofrequency ablation for
hepatocellular carcinoma. Br J Surg 2011;98:1210-24.
173. Sparchez Z, Mocan T, Radu P, Mocan LP, Sparchez M, et al. Prognostic factors after percutaneous radiofrequency ablation in the
treatment of hepatocellular carcinoma. Impact of incomplete ablation on recurrence and overall survival rates. J Gastrointest Liver Dis
2018;27:399-407.
174. Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, et al. Association between nucleoside analogues and risk of hepatitis B virus-related
hepatocellular carcinoma recurrence following liver resection. JAMA 2012;308:1906-13.
175. N’Kontchou G, Mahamoudi A, Aout M, Ganne-Carrié N, Grando V, et al. Radiofrequency ablation of hepatocellular carcinoma: long-
term results and prognostic factors in 235 western patients with cirrhosis. Hepatology 2009;50:1475-83.
176. European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice
Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015;63:237-64.
177. Rekik S, Allaire M, Mumana A, Guyot E, Nkontchou G, et al. Transient elastography predicts survival after radiofrequency ablation of
hepatocellular carcinoma developing on cirrhosis. J Gastroenterol Hepatol 2020;35:142-50.
178. Llovet JM, Real MI, Montaña X, Planas R, Coll S, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in
patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9.
179. Kong J, Li S, Fan H, Zhang L, Zhao H, et al. Transarterial chemoembolization extends long-term survival in patients with unresectable
hepatocellular carcinoma. Medicine (Baltimore) 2018;97:e11872.
180. Liapi E, Georgiades CC, Hong K, Geschwind JFH. Transcatheter arterial chemoembolization: current technique and future promise. Tech
Vasc Interv Radiol 2007;10:2-11.
181. Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol
2015;62:1187-95.
182. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, et al. Comparison of conventional transarterial chemoembolization (TACE)
and chemoembolization with doxorubicin Drug Eluting Beads (DEB) for unresectable Hepatocelluar Carcinoma (HCC). J Surg Oncol
2010;101:476-80.
183. Poon RTP, Tso WK, Pang RWC, Ng KKC, Woo R, et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a
novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007;5:1100-8.
184. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, et al. Expression of vascular endothelial growth factor in human
hepatocellular carcinoma. Hepatology 1998;28:68-77.
185. Ogasawara S, Yano H, Iemura A, Hisaka T, Kojiro M. Expressions of basic fibroblast growth factor and its receptors and their relationship
to proliferation of human hepatocellular carcinoma cell lines. Hepatology 1996;24:198-205.
186. Zhu CB, Wang C, Chen LL, Ma GL, Zhang SC, et al. Serum YKL-40 independently predicts outcome after transcatheter arterial
chemoembolization of hepatocellular carcinoma. PLoS One 2012;7:e44648.
187. Casadei Gardini A, Conti F, Foschi FG, Brillanti S, Andreone P, et al. Imbalance of neutrophils and lymphocyte counts can be
predictive of hepatocellular carcinoma occurrence in hepatitis C-related cirrhosis treated with direct-acting antivirals. Gastroenterology
2018;154:2281-2.
188. Casadei Gardini A, Foschi FG, Conti F, Petracci E, Vukotic R, et al. Immune inflammation indicators and ALBI score to predict liver
cancer in HCV-patients treated with direct-acting antivirals. Dig Liver Dis 2019;51:681-8.
189. Wang B, Li F, Cheng L, Zhan Y, Wu B, et al. The pretreatment platelet count is an independent predictor of tumor progression in patients
undergoing transcatheter arterial chemoembolization with hepatitis B virus-related hepatocellular carcinoma. Futur Oncol 2019;15:827-
39.
190. Wu YQ, Fan WZ, Xue M, Guo J, Wei JL, et al. 25-OH-vitamin D deficiency identifies poor tumor response in hepatocellular carcinoma
treated with transarterial chemoembolization. Clin Transl Oncol 2020;22:70-80.
191. Zhang JB, Chen Y, Zhang B, Xie X, Zhang L, et al. Prognostic significance of serum gamma-glutamyl transferase in patients with